ARDX vs REGN · rev $215.3M vs P/E 14, rev $4.29B
Ardelyx Inc (ARDX) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Ardelyx Inc (ARDX) is a biotechnology company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US. It is led by Leonard S. Schleifer M.D., Ph.D..
Latest reported ARDX revenue for 2026-06-30 was $215.3M. Net income was -$54.3M. ARDX currently screens at market cap $1.37B.
Latest reported REGN revenue for 2026-06-30 was $4.29B. Net income was $1.30B. Revenue was up 19.0% from 2026-03-31 to 2026-06-30. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
ARDX currently screens at market cap $1.37B. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the ARDX and REGN stock pages for the full models.
Not investment advice.